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Editorial Comment 
Tissue Plasminogen Activator: 
Why the Backlash?* 
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ROBERT M. CALIFF, MD, FACCS 
Ann Arbor, Michigan and Durham, North Carolina 
In recent months since the approval of intravenous throm- 
bolytic agents in the United States, recombinant tissue 
plasminogen activator (rt-PA) has been under fire in many 
peer review medical journal articles (l-4). At issue is 
whether rt-PA, an expensive, elegant product of the molec- 
ular biology revolution, is really better than streptokinase, 
an inexpensive bacterial protein produced by routine labo- 
ratory methods. The cumulative data base from 13 angio- 
graphic studies (5-17) indicates that infarct vessel patency at 
60 to 120 min was achieved approximately 50% more fre- 
quently with r&PA compared with streptokinase (75% versus 
48%, respectively) for 1,738 patients treated at 2.9 h from 
symptom onset. However, a definite “catch-up” phenome- 
non for streptokinase has been documented (17) by serial 
angiography performed up to 24 h after symptom onset. By 
the time of late follow-up cardiac catheterization, the pa- 
tency rate of arteries treated with agents lacking fibrin 
selectivity is similar to that of patients treated with rt-PA. 
Thus, although rt-PA holds promise for improved earfy 
coronary thrombolytic action, it has not yet been demon- 
strated whether this effect translates into superior preserva- 
tion of left ventricular function or a reduction of mortality. 
Left ventricular function. In this issue of the Journal, 
Armstrong et al. (18), from 10 Toronto hospitals (TPAT), 
report a placebo-controlled trial of rt-PA in left ventricular 
function. It is the first study of the predominantly two chain 
Burroughs-Wellcome preparation of rt-PA, which has dem- 
onstrated efficacy beyond coronary thrombolysis. The dos- 
ing in megaunits per kilogram, is, however, quite different 
from that of most previous trials (5-8) of this fibrinolytic 
agent, although weight-adjusted dosing has previously been 
associated with improved infarct vessel patency, less reoc- 
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elusion and a lower bleeding complication rate compared 
with a fixed dosage regimen (19). 
This trial (18) becomes the fifth consecutive randomized 
placebo-controlled trial of rt-PA, each of which has demon- 
strated significant improvement in convalescent phase car- 
diac function (Table 1) (20-23). In parallel, streptokinase has 
been shown in three randomized studies (24-26) to improve 
cardiac function to a similar degree. Recently, two new trials 
directly compared rt-PA with streptokinase. Using two- 
dimensional echocardiography in 126 randomly assigned 
patients, Magnani et al. (27) reported better left ventricular 
function with rt-PA. In a larger trial of 270 patients designed 
to examine differences in ejection fraction by contrast ven- 
triculography at 21 days, White et al. (28) found the value 
(58 2 12%) to be identical for the two agents. Thus, major 
differences between the agents for recovery of ventricular 
function are unlikely. 
Mortality. Improvement in survival has now been un- 
equivocally proved for three thrombolytic agents, in sepa- 
rately performed large randomized controlled trials of strep- 
tokinase (29,30), rt-PA (31) and anisoylated plasminogen 
streptokinase activator complex (ASPAC) (32). These four 
studies differed with respect to control group mortality, 
inclusion criteria, time to treatment and adjunctive therapy, 
making intertrial comparisons difficult. Nonetheless, meta 
analysis shows a similar risk reduction for all three agents 
(33). Despite the lack of overall differences in cardiac 
functional improvement in the four relatively small but direct 
comparative trials (5,27,28,34), a 29% further reduction in 
mortality was conferred by rt-PA (Table 2). Perhaps this 
mortality difference is related to the earlier establishment of 
arterial patency achieved with rt-PA. However, true differ- 
ences in mortality reduction among the agents will only be 
established from the ongoing second Gruppo Italian0 per lo 
Studio della Sopravivenza nell’lnfarto Miocardico (GISSI-2) 
trial and the International Studies of Infarct Survival (ISIS-3) 
trial, the latter of which will begin this year, using the 
Burroughs-Wellcome rt-PA preparation, streptokinase and 
anisoylated plasminogen streptokinase activator complex. 
Other aspects. Speculation has ranged from a prediction 
that rt-PA would be associated with less bleeding because of 
the absence of a systemic lytic state (35,36) to a fear that it 
would result in an increased risk of bleeding secondary to 
augmented fibrinolytic potency (1,2,37). Direct comparative 
trial data show little difference in extracranial bleeding 
complications, except for a slight advantage with rt-PA in 
two of the four trials (5,27,28,34). In the largest study of 
rt-PA in terms of patients treated, the recently completed 
Thrombolysis in Myocardial Infarction (TIMI-II) trial (38), 
the incidence of intracranial hemorrhage was 0.5% in 2,742 
patients treated with 100 mg (manufacturer’s recommended 
01989 by the American College of Cardiology O-715.1097/89/$3.50 
1478 TOPOL AND CALIFF JACC Vol. 13, No. 7 
EDITORIAL COMMENT June 1989: 1477-80 
Table 1. Intravenous Thrombolytic Intervention for Acute Myocardial Infarction: Eight Placebo-Controlled Randomized Trials 
Trial (reference) 
No. of 
Patients 
Time 
to Rx 
(h) 
Time 
Assessed 
(day) Method 
Ejection Fraction (%) 
Thrombolytic 
Agent Placebo 
Tissue plasminogen activator 
Johns Hopkins (20) 
TIC0 (22) 
National Heart Foundation (21) 
European Cooperative Study Group (23) 
TPAT (18) 
Streptokinase 
White et al. (26) 
Western Washington (25) 
ISAM (24) 
138 3.2 IO 
126 1.9 21 
144 3.25 7 
121 2.9 14 
115 3.0 9 
219 3.0 
368 3.5 
848 <6.0 
21 
10 
21 
53.2 46.4 
61.0 54.0 
51.7 51.7 
50.7 48.5 
53.6 47.8 
59.0 
54.3 
56.8 
53.0 
50.7 
53.9 
All differences (thrombolytic agents versus placebo) in global ejection fraction were significant (p < 0.05) except in the Western Washington study (p = 0.056). 
C = contrast (radiographic); ISAM = Intravenous Streptokinase for Acute Myocardial Infarction; N = radionuclide; Rx = therapy; TIC0 = Thrombolysis in 
Coronary Occlusion; TPAT = Tissue Plasminogen Activator: Toronto. 
dose) (39). As opposed to the other large mortality trials (29- 
32), this overall low frequency was established with detailed 
data collection and routine computed axial tomographic 
scanning for any new neurologic deficit. 
A major practical difference in clinical strategies between 
the agents is highlighted by the excellent overall clinical 
outcome of the TPAT patients, who were treated with a 
conservative strategy of coronary revascularization after 
r&PA (18), a finding that corroborates the results of several 
major randomized clinical trials (8,10,13,38). No randomized 
trials evaluating the most appropriate revascularization 
strategy after streptokinase have been completed, although 
observational data indicate that early angioplasty may be 
more beneficial after streptokinase than after rt-PA to com- 
pensate for the slower clot lysis rate with nonfibrin-specific 
agents (15,40). Other important practical considerations fa- 
voring rt-PA include its lack of allergic or antigenic side 
effects, avoidance of directly induced hypotension and rela- 
tive time-independent thrombolytic effect (41). 
Why the backlash? Recombinant tissue plasminogen ac- 
tivator (rt-PA) is a product of the exciting new biotechnolo- 
gic era and, over the past 5 years, has been applied to a high 
profile disease state. These factors have led to considerable 
hype in the scientific literature and media. The IO-fold price 
Table 2. Mortality in Eight Randomized Clinical Trials of Intravenous Thrombolytic Therapy 
Trial (reference) 
Thrombolytic 
Agents 
No. of 
Patients 
Mortality 
Treatment Control 
(%) (%) 
Thrombolytic agent vs. control 
GISSI (29) SK 11,806 10.7 13.0 
ISIS-2 (30) SK 17,187 9.2 12.0 
ASSET (3 1) rt-PA 5,011 7.2 9.8 
AIMS (32) APSAC 1,004 6.3 12.1 
Streptokinase versus r&PA* SK it-PA 
TIMI- (34) 306 8.8 7.6 
ECSG-1 (5) 129 4.7 4.6 
PAIMS (27) 171 8.2 4.6 
White et al. (28) 271 7.3 3.7 
- - 
Pooled 887 7.6 5.4 
*If actual treatment is considered rather than intention to treat, the pooled mortality rate for streptokinase and 
r&PA therapy was 7.4% versus 4.4%, respectively, which represents a 40% decrease in favor of t-PA. AIMS = 
APSAC Intervention Mortality Study; APSAC = anisoylated plasminogen streptokinase activator complex; ECSG 
= European Cooperative Study Group; GISSI = Gruppo Italian0 per lo Studio della Streptochinasi nell’lnfarto 
Miocardico; ISIS-2 = International Study of Infarct Survival; PAIMS = Plasminogen Activator Italian Multicenter 
Study; r&PA = recombinant tissue plasminogen activator; SK = streptokinase; TIM1 = Thrombolysis in Myocardial 
Infarction. 
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differential between rt-PA and streptokinase is most unfor- 
tunate. Tissue plasminogen activator clearly does not open 
10 times as many arteries, save 10 times as much heart 
muscle or save 10 times as many lives. Perhaps never before 
has a price difference in therapeutic alternatives fueled so 
much debate and further clinical investigation. Only when 
the GISSI-2 and ISIS-3 trials are completed will we know for 
certain whether tissue plasminogen activator’s more rapid 
achievement of coronary artery patency represents a life- 
saving advantage. Were there no cost differences between 
fibrinolytic agents, these major trials would probably not 
have been performed. Thus, the backlash and acrimony over 
rt-PA has largely been driven by economic issues. The 
interaction of two powerful streams of medical thought, 
reperfusion and cost-consciousness, has served the useful 
purpose of heightening clinicians’ awareness of the critical 
issues confronting modern medicine on both fronts. 
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